AU2021387993A1 - Treatment of public speaking anxiety with an alpha-7 nicotinic acetylcholine receptor agonist - Google Patents

Treatment of public speaking anxiety with an alpha-7 nicotinic acetylcholine receptor agonist Download PDF

Info

Publication number
AU2021387993A1
AU2021387993A1 AU2021387993A AU2021387993A AU2021387993A1 AU 2021387993 A1 AU2021387993 A1 AU 2021387993A1 AU 2021387993 A AU2021387993 A AU 2021387993A AU 2021387993 A AU2021387993 A AU 2021387993A AU 2021387993 A1 AU2021387993 A1 AU 2021387993A1
Authority
AU
Australia
Prior art keywords
sad
individual
compound
symptom
fear
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021387993A
Other languages
English (en)
Other versions
AU2021387993A9 (en
Inventor
Yunsheng He
Christos POLYMEROPOULOS
Mihael Polymeropoulos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanda Pharmaceuticals Inc
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of AU2021387993A1 publication Critical patent/AU2021387993A1/en
Publication of AU2021387993A9 publication Critical patent/AU2021387993A9/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
AU2021387993A 2020-11-25 2021-11-24 Treatment of public speaking anxiety with an alpha-7 nicotinic acetylcholine receptor agonist Pending AU2021387993A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063118121P 2020-11-25 2020-11-25
US202063118132P 2020-11-25 2020-11-25
US63/118,132 2020-11-25
US63/118,121 2020-11-25
US202163158449P 2021-03-09 2021-03-09
US63/158,449 2021-03-09
PCT/US2021/060720 WO2022115526A1 (en) 2020-11-25 2021-11-24 Treatment of public speaking anxiety with an alpha-7 nicotinic acetylcholine receptor agonist

Publications (2)

Publication Number Publication Date
AU2021387993A1 true AU2021387993A1 (en) 2023-06-08
AU2021387993A9 AU2021387993A9 (en) 2024-02-08

Family

ID=78957498

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021387993A Pending AU2021387993A1 (en) 2020-11-25 2021-11-24 Treatment of public speaking anxiety with an alpha-7 nicotinic acetylcholine receptor agonist

Country Status (8)

Country Link
US (1) US20230381169A1 (https=)
EP (1) EP4251158A1 (https=)
JP (1) JP2023553354A (https=)
KR (1) KR20230112622A (https=)
AU (1) AU2021387993A1 (https=)
CA (1) CA3199760A1 (https=)
MX (1) MX2023005895A (https=)
WO (1) WO2022115526A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0220581D0 (en) * 2002-09-04 2002-10-09 Novartis Ag Organic Compound
GB0424564D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds
JP6263469B2 (ja) 2011-07-15 2018-01-17 ノバルティス アーゲー アザ二環式ジ−アリールエーテルの塩およびその製造方法またはその前駆体の製造方法
EP2742940B1 (en) * 2012-12-13 2017-07-26 IP Gesellschaft für Management mbH Fumarate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-l-aza-bicyclo-[2.2.2]octane for adminstration once daily, twice daily or thrice daily

Also Published As

Publication number Publication date
AU2021387993A9 (en) 2024-02-08
CA3199760A1 (en) 2022-06-02
JP2023553354A (ja) 2023-12-21
US20230381169A1 (en) 2023-11-30
EP4251158A1 (en) 2023-10-04
KR20230112622A (ko) 2023-07-27
WO2022115526A1 (en) 2022-06-02
MX2023005895A (es) 2023-06-06

Similar Documents

Publication Publication Date Title
TWI553006B (zh) 依託拉嗪(eltoprazine)於治療與神經或心理疾病有關之認知失能之症狀的用途
JP2022514194A (ja) 自殺のリスクを低減し、うつ病を迅速に軽減するためのガボキサドール
US11826321B2 (en) Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
KR20250005181A (ko) 인지 기능장애 치료
CN104884053B (zh) 用于改善记忆表现的益智组合物
US20240082225A1 (en) Methods for the treatment of dyskinesia in cerebral palsy
JPWO2018221728A1 (ja) アルツハイマー型認知症予防または治療剤
US20220062265A1 (en) Dose regimens for use of ly3154207 in the treatment of dopaminergic cns disorders
JP7822954B2 (ja) ダリドレキサントの医学的用途
AU2021387993A1 (en) Treatment of public speaking anxiety with an alpha-7 nicotinic acetylcholine receptor agonist
RU2840314C1 (ru) Лечение боязни публичного выступления агонистом альфа-7 никотинового ацетилхолинового рецептора
US20250205215A1 (en) Novel use of pitolisant for treating severe fatigue
US20240197698A1 (en) Treatment of acute anxiety with an alpha-7 nicotinic acetylcholine receptor modulator
CN116761604A (zh) 用α-7烟碱型乙酰胆碱受体激动剂治疗当众讲话焦虑
TW202302109A (zh) 認知損傷之治療
US20210283075A1 (en) Methods of treating attention deficit hyperactivity disorder
WO2026064558A1 (en) Use of reboxetine to treat narcolepsy
US20200038415A1 (en) Aminosterol compositions and methods of using the same for treating erectile dysfunction
TW202606707A (zh) 不具副作用之９－［４－（環己氧基）苯基］－７－甲基－３，４－二氫吡并［２，１－ｃ］［１，２，４］噻二－２，２－二氧化物投與方法
HK40112834A (zh) 用於痴呆和神经变性病况中的激越、精神病和认知衰退的环苯扎林治疗
JP2003525241A (ja) 機能性胃腸疾患治療用トラマドール
EA044015B1 (ru) Дейтетрабеназин для лечения дискинезии при церебральном параличе
WO2012048871A1 (en) Memantine for improving cognitive performance in subjects
HK1184674A (en) Treatment for neurological and mental disorders
HK1184674B (en) Treatment for neurological and mental disorders

Legal Events

Date Code Title Description
SREP Specification republished